Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Reckitt recalls Fybogel batches over metal fragment fears

Clinical Manufacturer fears gastric motility sachets may contain metal fragments

Reckitt Benckiser UK is recalling batches of its Fybogel sachets over fears they could contain metal fragments.


The MHRA yesterday (March 12) advised pharmacists to quarantine affected batches of Fybogel Orange (ispaghula husk) and return them to the original supplier for credit.


The sachets are used to aid gastric motility.


Medical queries should be directed to Reckitt Benckiser Healthcare on 0500 455 456, while stock enquiries should be directed to 01753 506950.


The affected batches are:


Batch number Expiry date Pack size First distributed
401010 January 2017 1 x 30 26 February 2014
401312 January 2017 1 x 30 1 March 2014

More recent medicine recalls

Gilead recalls Viread batches after manufacturing fault

Janssen-Cilag recalls Doribax powder

MSD recalls eye drops after package redesign

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD016871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel